Abstract
Telomerase, a ribonucleoprotein enzyme, is considered as a potential target of cancer therapy because of its preferential expression in tumors. In particular, malignant gliomas are one of the best candidates for telomerase-targeted therapy. It is because malignant gliomas are predominantly telomerase-positive, while normal brain tissues do not express telomerase. In theory, there are two telomerase-associated therapeutic approaches for telomerase-positive tumors. One approach is the anti-telomerase cancer therapy to directly inhibit telomerase activity, resulting in apoptotic cell death or growth arrest. Two major components of the telomerase holoenzyme complex, the RNA template (hTER) and catalytic subunit (reverse transcriptase, hTERT) are well considered as therapeutic targets. The other approach is the telomerase-specific cancer therapy by targeting telomerase-expressing tumor cells as a means to directly kill the cells. Strategies using the transfer of therapeutic gene under the hTERT promoter system as well as immunotherapy directed against telomerase-positive cells are generally included. These telomerase-associated therapies are very promising for the treatment of malignant gliomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A . 2000 Mol. Ther. 2: 539–544
Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R . 1997 Proc. Natl. Acad. Sci. USA 94: 2620–2625
Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S . 2001 Blood 97: 2903–2907
Betts L, Josey JA, Veal JM, Jordan SR . 1995 Science 270: 1838–1841
Blackburn EH . 1991 Nature 350: 569–573
Broccoli D, Young JW, de Lange T . 1995 Proc. Natl. Acad. Sci. USA 92: 9082–9086
Burger PC, Vogel FS, Green SB, Strike TA . 1985 Cancer 56: 1106–1111
Buzayan JM, Gerlach WL, Bruening G . 1986 Nature 323: 349–353
Carroll T, Maltby E, Brock I, Royds J, Timperley W, Jellinek D . 1999 J. Pathol. 188: 395–399
Cech TR, Zaug AJ, Grabowski PJ . 1981 Cell 27: 487–496
Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, Harley CB, Lansdorp PM . 1996 Stem Cells 14: 239–248
Chong EYY, Lam PYP, Poon W-S, Ng H-K . 1998 Hum. Pathol. 29: 599–603
Cong YS, Wen J, Bacchetti S . 1999 Hum. Mol. Genet. 8: 137–142
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S . 1992 EMBO J. 11: 1921–1929
Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML . 1999 Cancer 85: 485–491
Deen DF, Chiarado A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, Rosenblum ML, Suit HD, Walker MD, Wikstrand CJ, Wilson CB, Wong AJ, Yung WKA . 1993 J. Neuro-Oncol. 16: 243–272
de Lange T . 1994 Proc. Natl. Acad. Sci. USA 91: 2882–2885
DeMasters BK, Markham M, Lillehei KO, Shroyer K . 1997 Am. J. Clin. Pathol. 107: 548–554
Falchetti ML, Pallini R, Larocca LM, Verna R, D'Ambrosio E . 1999 J. Clin. Pathol. 52: 234–236
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW, Villeponteau B . 1995 Science 269: 1236–1241
Gilley D, Blackburn EH . 1996 Mol. Cell. Biol. 16: 66–75
Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, Fang B . 2000 Cancer Res. 60: 5359–5364
Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JHM, Meyerson M, Weinberg RA . 1999 Nature Med. 5: 1164–1170
Harada K, Kurisu K, Tahara H, Tahara E, Ide T, Tahara E . 2000 J. Neurosurg. 93: 618–625
Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I, Robinson MO . 1997 Science 275: 973–977
Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J . 2001 Cancer Res. 61: 3388–3393
Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR . 1999 Proc. Natl. Acad. Sci. USA 96: 14276–14281
Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N . 1998 Cancer Res. 58: 2117–2125
Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA, Shay JW . 1995 J. Natl. Cancer Inst. 87: 895–902
Huang F, Kanno H, Yamamoto I, Lin Y, Kubota Y . 1999 J. Neurooncol. 43: 137–142
Johnson OL, Jaworowicz W, Cleland JL, Bailey L, Charnis M, Duenas E, Wu C, Shepard D, Magil S, Last T, Jones AJ, Putney SD . 1997 Pharm. Res. 14: 730–735
Kanazawa Y, Ohkawa K, Ueda K, Mita E, Takehara T, Sasaki Y, Kasahara A, Hayashi N . 1996 Biochem. Biophys. Res. Commun. 225: 570–576
Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T . 1999 Science 283: 1321–1325
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW . 1994 Science 266: 2011–2015
Kleinschmidt-DeMasters BK, Hashizumi TL, Sze C-I, Lillehei KO, Shroyer AL, Shroyer KR . 1998 J. Clin. Pathol. 51: 284–293
Kleinschmidt-DeMasters BK, Evans LC, Bobak JB, Lopez-Uribe D, Hopper D, Shroyer AL, Shroyer KR . 2000 Hum. Pathol. 31: 905–913
Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S . 2000 Hum. Gene. Ther. 11: 1397–1406
Koga S, Kondo Y, Komata T, Kondo S . 2001a Gene Ther. 8: 654–658
Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, Kyo S, Kondo S . 2001b Anticancer Res. 21: 1937–1943
Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S . 2000 Gene Ther. 7: 2071–2079
Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, Srinivasula SM, Barna BP, Germano IM, Takakura M, Inoue M, Alnemri ES, Shay JW, Kyo S, Kondo S . 2001 Cancer Res. 61: 5796–5802
Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, Liu J, Haqqi T, Nishiyama A, Villeponteau B, Cowell JK, Barna BP . 1998a FASEB J. 12: 801–811
Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK . 1998b Oncogene 16: 3323–3330
Kondo Y, Koga S, Komata T, Kondo S . 2000 Oncogene 19: 2205–2211
Kondo Y, Komata T, Kondo S . 2001 Int. J. Oncol. 18: 1287–1292
Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy AW, Silverman RH, Cowell JK . 2000 Gynecol. Oncol. 76: 183–192
Langford LA, Piatyszek MA, Xu R, Schold Jr SC, Shay JW . 1995 Lancet 346: 1267–1268
Le S, Zhu JJ, Anthony DC, Greider CW, Black PM . 1998 Neurosurgery 42: 1120–1125
Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, von Zglinicki T . 2001 Cancer Res. 61: 3053–3061
Mahaley Jr MS, Mettlin C, Natarajan N, Laws Jr ER, Peace BB . 1989 J. Neurosurg. 71: 826–836
Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP . 2001 Gene Ther. 8: 568–578
Maran A, Maitra RK, Kumar A, Dong B, Xiao W, Li G, Williams BRG, Torrence PF, Silverman RH . 1994 Science 265: 789–792
Melana SM, Holland JF, Pogo BG . 1998 Clin. Cancer Res. 4: 693–696
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidpoff ML, Liu Q, Bacchetti S, Haber DA, Weinberg RA . 1997 Cell 90: 785–795
Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M . 2000 Proc. Natl. Acad. Sci. USA 97: 4796–4801
Mukai S, Kondo Y, Koga S, Komata T, Barna BP, Kondo S . 2000 Cancer Res. 60: 4461–4467
Multani AS, Furlong C, Pathak S . 1998 Int. J. Oncol. 13: 923–925
Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E . 2000 Nat. Med. 6: 1011–1017
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Linger J, Harley CB, Cech TR . 1997 Science 277: 955–959
Nakayama J, Saito M, Nakamura H, Matsuura A, Ishikawa F . 1997 Cell 88: 875–884
Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR . 1996 Nat. Biotechnol. 14: 615–619
Ostenfeld T, Caldwell MA, Prowse KR, Linskens MH, Jauniaux E, Svendsen CN . 2000 Exp. Neurol. 164: 215–226
Piepmeier JM, Christopher S . 1997 J. Neurooncol. 34: 1–3
Pitts AE, Corey DR . 1998 Proc. Natl. Acad. Sci. USA 95: 11549–11554
Putney SD, Burke PA . 1998 Nat. Biotechnol. 16: 153–157
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R . 1998 Cancer Res. 58: 622–625
Roth W, Weller M . 1999 Cell Mol. Life Sci. 56: 481–506
Sallinen P, Miettinen H, Sallinen S-L, Haapasalo H, Helin H, Kononen J . 1997 Am. J. Pathol. 150: 1159–1164
Sano T, Asai A, Mishima K, Fujimaki T, Kirino T . 1998 Br. J. Cancer 77: 1633–1637
Schoenberg BS . 1983 Walker MD (ed) Nijhoff, Boston 1–30
Shammas MA, Simmons CG, Corey DR, Shmookler, Reis RJ . 1999 Oncogene 18: 6191–6200
Silverman RH . 1997 G D'Alessio and JF Riordan (ed) Academic Press, Inc 515–551
Strahl C, Blackburn EH . 1994 Nucleic Acids Res. 22: 893–900
Strahl C, Blackburn EH . 1996 Mol. Cell. Biol. 16: 53–65
Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M . 1999 Cancer Res. 59: 551–557
Tejera AM, Alonso DF, Gomez DE, Olivero OA . 2001 Breast Cancer Res. Treat. 65: 93–99
Tzfati Y, Fulton TB, Roy J, Blackburn EH . 2000 Science 288: 863–867
Vonderheide RH, Hahn WC, Schultze JL, Nadler LM . 1999 Immunity 10: 673–679
Weil RJ, Wu Y-Y, Vortmeyer AO, Moon Y-W, Delgado RM, Fuller BG, Lonser RR, Remaley AT, Zhuang Z . 1999 Mod. Pathol. 12: 41–46
Weng NP, Levine BL, June CH, Hodes RJ . 1996 J. Exp. Med. 183: 2471–2479
White LK, Wright WE, Shay JW . 2001 Trends Biotechnol. 19: 114–120
Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW . 1996 Dev. Genet. 18: 173–179
Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T . 1998 Cancer Res. 58: 5406–5410
Yokoyama Y, Takahashi Y, Shinohara A, Wan X, Takahashi S, Niwa K, Tamaya T . 2000 Biochem. Biophys. Res. Commun. 273: 316–321
Zhang X, Mar V, Zhou W, Harrington L, Robinson MO . 1999 Gene Dev. 13: 2388–2399
Zhu J, Zhang L, Hanisch UK, Felgner PL, Reszka R . 1996 Gene Ther. 3: 472–476
Acknowledgements
Our research involving the development of 2–5A-anti-hTER and hTERT/caspase family systems is supported in part by the Cleveland Clinic Foundation Research Funds No. 5928 and No. 6200 (S Kondo), the John Gagliarducci Fund (S Kondo), and the NIH grants CA80233 and CA88936 (S Kondo).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Komata, T., Kanzawa, T., Kondo, Y. et al. Telomerase as a therapeutic target for malignant gliomas. Oncogene 21, 656–663 (2002). https://doi.org/10.1038/sj.onc.1205072
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205072
Keywords
This article is cited by
-
Hyperpolarized δ-[1- 13C]gluconolactone imaging visualizes response to TERT or GABPB1 targeting therapy for glioblastoma
Scientific Reports (2023)
-
Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells
Cytotechnology (2018)
-
Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?
Current Treatment Options in Neurology (2018)
-
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
Journal of Neuro-Oncology (2016)
-
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Oncogene (2006)